The opioid addiction market is dominated by opioid receptor agonist therapies for the maintenance treatment of opioid addiction, most notably generic methadone and Indivior’s Suboxone Film. The…
Numerous drugs across multiple drug classes are available and used as monotherapies and/or adjunctive therapies for the treatment of bipolar disorder (BPD). The treatment armamentarium for BPD is…
Numerous drugs across multiple drug classes are available and used as monotherapies and/or adjunctive therapies for the treatment of bipolar disorder (BPD). The treatment armamentarium for BPD is…
MARKET OUTLOOK The moderate to severe AD market is at the beginning of a revolution with the recent approval of the first targeted AD biologic, Sanofi/Regeneron’s Dupixent, and a promising…
Marketed therapies are often sufficient in early stages of Parkinson’s disease (PD), but as the disease progresses, they impose a considerable pill burden, progressively lose efficacy, and are…
Marketed therapies are often sufficient in early stages of Parkinson’s disease (PD), but as the disease progresses, they impose a considerable pill burden, progressively lose efficacy, and are…
In the atopic dermatitis market, topical therapies have been the mainstay of treatment, especially for patients with a mild to moderate form of the disease. Conventional systemic immunosuppressants…
The atopic dermatitis (AD) market is poised to undergo a revolution owing to recent advances in understanding of disease pathology, the recent approval of topical crisaborole (Pfizer’s Eucrisa)…
Immune checkpoint inhibitors continue to revolutionize the treatment of a wide range of solid-tumor and hematological malignancies, with a growing list of approvals and label expansions. The Immune…
Atopic dermatitis (AD) is a chronic, pruritic inflammatory skin disease that usually affects children but can persist or start in adulthood. For many years, the treatment landscape has remained…
AD is a chronic inflammatory skin disease marked by pruritus, eczema, and, in moderate to severe patients, frequent relapse. Standard AD treatments aim to protect the skin barrier through…
The revolution in genomic sciences has spurred significant drug development in rare diseases, approximately 80% of which have a genetic etiology. The field of gene-based therapies, while still in…
The psoriasis market has become increasingly lucrative owing to the growing use of biologics in the moderate to severe population who cannot be adequately controlled with topical agents. The…
Market Outlook The expedited approvals of Novartis’s Kymriah for the treatment of pediatric and young adult patients with relapsed or refractory B-cell acute lymphocytic leukemia (ALL), and…
The migraine market stands on the verge of a renaissance; new and exciting therapies targeting the CGRP peptide could reach the market beginning in 2018. Two broad types of approaches are in final…
